- Home
- BMRN
as 04-17-2025 10:32am EST
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
Upcoming Earnings Alert:
Get ready for potential market movements as BioMarin Pharmaceutical Inc. BMRN prepares to release earnings report on 23 Apr 2025.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | NOVATO |
| Market Cap: | 13.7B | IPO Year: | 1999 |
| Target Price: | $94.00 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Buy | Number of Analysts: | 22 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.21 | EPS Growth: | 153.71 |
| 52 Week Low/High: | $52.93 - $94.85 | Next Earning Date: | 04-23-2025 |
| Revenue: | $2,853,915,000 | Revenue Growth: | 17.97% |
| Revenue Growth (this year): | 12.23% | Revenue Growth (next year): | 9.93% |
Stock Insider Trading Activity of BioMarin Pharmaceutical Inc. (BMRN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Burkhart Erin | BMRN | GVP, Chief Accounting Officer | Mar 19 '25 | Sell | $71.52 | 1,295 | $92,618.40 | 16,955 | |
| Guyer Charles Greg | BMRN | EVP, Chief Technical Officer | Mar 6 '25 | Sell | $71.28 | 7,034 | $501,355.38 | 87,655 | |
| Burkhart Erin | BMRN | GVP, Chief Accounting Officer | Feb 24 '25 | Sell | $68.38 | 1,344 | $91,902.72 | 16,955 |
Latest BioMarin Pharmaceutical Inc. News
BMRN Breaking Stock News: Dive into BMRN Ticker-Specific Updates for Smart Investing
PR Newswire
3 hours ago
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET
Zacks
a day ago
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Zacks
a day ago
Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last?
StockStory
a day ago
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks
Argus Research
2 days ago
BMRN: Raising target price to $63.00
MT Newswires
2 days ago
Spruce Biosciences Acquires Tralesinidase Alfa From BioMarin
Motley Fool
6 days ago
6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility
Zacks
7 days ago
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?
Compare BMRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BMRN BioMarin Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.